Security Snapshot

Agios Pharmaceuticals, Inc. - Common Stock, Par Value $0.001 per share (AGIO) Institutional Ownership

CUSIP: 00847X104

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

168

Shares (Excl. Options)

44.98MFull value: 44,975,079 · shares · 30 Sep 2026

Price

$33.25

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+2,024,513
Value change
+$62,861,537
Number of holders
168
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
59,829,338
SEC-reported price per share
$33.25
Insider filing price
$33.25
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • AGIO - Agios Pharmaceuticals, Inc. - Common Stock, Par Value $0.001 per share is tracked under CUSIP 00847X104.
  • 168 institutions reported positions in Q3 2026.
  • 10 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 235 to 168 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $2.45BFull value: $2,451,840,378 · USD · 30 Jun 2026
    to
    $1.5BFull value: $1,495,405,361 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 168 institutions filings for Q3 2026.

Open SEC evidence

Security key

00847X104

13F reference period

Q3 2026

13F holders

168

13D/G owners

10

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
10
Security
AGIO
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FARALLON CAPITAL MANAGEMENT, L.L.C. 9.9% $239,950,570 5,917,400 Farallon Capital Management, L.L.C. 30 Jun 2026
Farallon Capital Partners, L.P. 8.8% -11% $146,117,182 -$14,583,696 5,159,505 -9.1% Dapice Joshua J. 31 Dec 2025
BlackRock, Inc. 7.8% $150,100,362 4,513,170 BlackRock, Inc. 30 Jun 2025
D. E. SHAW & CO, L.P. 6.5% +28% $129,306,158 +$28,424,627 3,888,907 +28% D. E. Shaw & Co., L.P. 30 Sep 2026
MORGAN STANLEY 5.7% $114,108,348 3,431,830 Morgan Stanley 30 Sep 2026
STATE STREET CORP 5.3% $88,022,666 3,108,145 STATE STREET CORPORATION 31 Dec 2025
VANGUARD CAPITAL MANAGEMENT LLC 5.3% $104,472,757 3,088,169 Vanguard Capital Management 31 Mar 2026
Paradigm Biocapital Advisors LP 4.9% -6% $115,344,498 -$6,198,499 2,873,555 -5.1% Paradigm BioCapital Advisors LP 30 Sep 2025
ARMISTICE CAPITAL, LLC 4.6% -13% $95,358,760 -$11,235,200 2,716,000 -11% Armistice Capital, LLC 31 Mar 2026
Lynx1 Capital Management LP 0.8% -86% $15,714,150 -$84,499,655 472,606 -84% Lynx1 Capital Management LP 30 Sep 2026
As of 30 Sep 2026, 168 institutional investors reported holding
44.98MFull value: 44,975,079 · shares · 30 Sep 2026
shares of Agios Pharmaceuticals, Inc. - Common Stock, Par Value $0.001 per share (AGIO). This represents 75% of the company’s total
59.83MFull value: 59,829,338 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
63%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FARALLON CAPITAL MANAGEMENT, L.L.C. 9.9% 5,939,400 +0.37% 1% $197,485,050
MORGAN STANLEY 5.7% 3,436,589 +257% 0.01% $114,266,614
STATE STREET CORP 5.5% 3,264,652 -7.6% 0% $108,549,679
VANGUARD PORTFOLIO MANAGEMENT LLC 4.8% 2,850,204 -1.7% 0% $94,769,283
VANGUARD CAPITAL MANAGEMENT LLC 4.5% 2,687,851 +0.22% 0% $89,371,046
ARMISTICE CAPITAL, LLC 4.3% 2,578,000 +7.4% 2.9% $85,718,500
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 3.3% 1,958,547 -7.2% 0.11% $65,121,688
Assenagon Asset Management S.A. 3.2% 1,886,412 +1715% 0.06% $62,723,199
GEODE CAPITAL MANAGEMENT, LLC 2.6% 1,582,178 +0.5% 0% $52,617,791
SUSQUEHANNA INTERNATIONAL GROUP, LLP 2.2% 1,319,476 -4.1% 0.04% $43,872,577
DIMENSIONAL FUND ADVISORS LP 2.1% 1,286,303 +3% 0.01% $42,769,288
GOLDMAN SACHS GROUP INC 1.9% 1,146,749 -0.36% 0% $38,129,404
TWO SIGMA INVESTMENTS, LP 1.5% 906,037 +69% 0.02% $30,125,730
Foresite Capital Management VI LLC 1.4% 827,128 +5.4% 4.9% $27,502,006
BANK OF AMERICA CORP /DE/ 1.2% 714,874 +41% 0% $23,769,575
Parkman Healthcare Partners LLC 1.1% 633,312 -5.3% 1.9% $21,057,624
SCS Capital Management LLC 1% 612,850 0% 0.18% $20,377,263
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1% 608,876 -25% 0.01% $20,245,127
Defilade Capital Management, L.P. 0.95% 570,318 +4.3% 3.2% $18,963,074
Qube Research & Technologies Ltd 0.93% 555,981 -7% 0.02% $18,486,368
RENAISSANCE TECHNOLOGIES LLC 0.85% 505,600 0.02% $16,811,200
Lynx1 Capital Management LP 0.79% 472,606 -86% 2.4% $15,714,150
Rock Springs Capital Management LP 0.79% 472,335 -11% 0.84% $15,705,139
GLENVIEW CAPITAL MANAGEMENT, LLC 0.77% 459,792 0.27% $15,288,084
Legal & General Group Plc 0.7% 418,633 -3.7% 0% $13,919,546

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
51
Headline period
Q3 2026
Rows shown
1-25 of 51
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 44,975,079 $1,495,405,361 +$62,861,537 $33.25 168
2026 Q2 66,003,474 $2,451,840,378 +$129,208,828 $37.11 235
2026 Q1 63,077,301 $2,120,792,628 +$71,838,431 $33.83 232
2025 Q4 61,265,073 $1,667,804,671 -$303,649,463 $27.22 237
2025 Q3 63,487,439 $2,545,616,686 +$81,769,351 $40.14 216
2025 Q2 61,683,672 $2,051,725,997 +$65,237,829 $33.26 211
2025 Q1 59,963,279 $1,757,322,194 -$10,187,060 $29.30 216
2024 Q4 59,832,436 $1,966,429,716 +$37,958,970 $32.86 221
2024 Q3 58,096,571 $2,582,267,784 -$8,181,474 $44.43 204
2024 Q2 58,132,966 $2,506,935,894 -$125,225,015 $43.12 203
2024 Q1 61,946,791 $1,811,267,450 +$89,235,062 $29.24 183
2023 Q4 59,884,422 $1,333,701,271 +$15,853,345 $22.27 167
2023 Q3 59,110,077 $1,463,036,585 -$8,921,651 $24.75 142
2023 Q2 59,366,269 $1,679,785,246 +$16,420,594 $28.32 150
2023 Q1 58,996,438 $1,355,139,176 -$9,985,145 $22.97 161
2022 Q4 59,442,573 $1,669,125,079 +$45,133,345 $28.08 156
2022 Q3 57,972,960 $1,639,524,356 -$46,396,034 $28.28 155
2022 Q2 59,017,906 $1,308,562,484 -$21,425,021 $22.17 143
2022 Q1 59,895,743 $1,743,443,247 +$19,219,573 $29.11 146
2021 Q4 59,210,281 $1,947,305,194 -$73,787,635 $32.87 148
2021 Q3 60,890,488 $2,810,077,563 -$244,072,957 $46.15 157
2021 Q2 65,926,694 $3,632,531,095 +$51,380,893 $55.11 179
2021 Q1 65,233,267 $3,366,007,585 +$56,136,770 $51.64 168
2020 Q4 64,981,734 $2,817,090,446 -$19,419,372 $43.33 189
2020 Q3 65,869,834 $2,304,359,620 -$101,763,130 $35.00 206
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .